Navigation Links
Mylan Declares Quarterly Preferred Stock Dividend
Date:4/16/2009

PITTSBURGH, April 16 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that in accordance with its 2.139 million preferred stock issuance, the company has declared its quarterly dividend of $16.25 per share (based on the annual dividend rate of 6.5% and a liquidation preference of $1,000.00 per share) payable on May 15, 2009, to holders of preferred stock of record as of May 1, 2009.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. Mylan Confirms First-to-File Patent Challenge Relating to Xeloda(R) Cancer Treatment
2. Andrew G. Cuneo Joins Mylan as Vice President of Global Business Development
3. Mylan Announces Clarinex(R) Settlement Agreement
4. Mylan Announces Intention to Purchase Remaining Interest in Matrix Laboratories and Delist Matrix from Indian Stock Exchanges
5. Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for First Generic, Heat-Stable Version of HIV Protease Inhibitor
6. Mylans Matrix Receives WHO Approval for First Generic, Heat-Stable Version of HIV Protease Inhibitor
7. Mylan Announces Transition of Chief Financial Officer
8. Mylan Vice Chairman and CEO Robert J. Coury to Ring NASDAQ Stock Market Opening Bell
9. Mylan Schedules Fourth Quarter Financial Results Conference Call and Live Webcast
10. Mylan Receives FDA Approval for First-to-File Generic Depakote(R) ER
11. Mylan Declares Quarterly Preferred Stock Dividend
Post Your Comments:
*Name:
*Comment:
*Email: